NOMAD POWER SOLUTIONS, INC. NMAD
Company is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development
and developing and commercializing cancer therapies. The Company's drug product pipeline is primarily focused on inhibitors of
protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies.
The Company believes that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | — | — | — | — | — | — | — | — | — | $25.0K |
| R&D | $254.9K | $726.2K | $898.1K | $1.3M | $1.7M | $1.2M | $820.9K | $40.7K | $467.3K | $870.0K |
| SG&A | $4.9M | $2.8M | $4.2M | $2.5M | $3.0M | $765.1K | $1.7M | $2.1M | $1.3M | $1.3M |
| Total operating expenses | $5.1M | $3.6M | $5.1M | $6.3M | $6.7M | $3.3M | $2.5M | $2.1M | $1.8M | $2.1M |
| Operating income | -$5.1M | -$3.6M | -$5.1M | -$6.3M | -$6.7M | -$3.3M | -$2.5M | -$2.1M | -$1.8M | -$2.1M |
| Interest expense | $9.2K | $16.8K | $16.2K | $8.9K | $7.4K | $3.7K | — | — | — | — |
| Pre-tax income | -$6.1M | — | — | — | — | — | — | — | — | — |
| Income tax | $1.6K | — | — | — | — | — | — | — | — | — |
| Net income | -$6.1M | -$3.6M | -$5.1M | -$6.3M | -$6.7M | -$3.3M | -$2.4M | -$2.1M | -$1.8M | -$2.1M |
| EPS, basic | — | -1.59 | -2.66 | -3.99 | -0.50 | — | — | — | — | — |
| EPS, diluted | -1.26 | -1.59 | -2.66 | -3.99 | -0.50 | -0.29 | -0.22 | -0.04 | -0.03 | -0.04 |
| Shares, diluted (wtd. avg.) | $4.8M | $2.2M | $1.9M | $1.6M | $13.5M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | $4.2M | $5.4M | $4.8M | $5.1M | $2.6M | $4.3M | $1.3M | $199.9K |
| Total current assets | $5.2M | $1.1M | $4.3M | $5.6M | $5.1M | $5.2M | $2.7M | $4.3M | $1.4M | $433.4K |
| Property, plant and equipment | $6.6M | — | — | — | — | — | — | — | — | — |
| Total assets | $12.7M | $1.1M | $4.3M | $5.6M | $5.1M | $5.2M | $2.7M | $4.3M | $1.4M | $433.4K |
| Accounts payable | $436.5K | $83.2K | $156.8K | $230.7K | $226.0K | $190.3K | $143.5K | $195.2K | $312.0K | $159.6K |
| Total current liabilities | $1.3M | $318.3K | $313.9K | $395.8K | $302.9K | $216.5K | $237.9K | $210.9K | $373.0K | $218.7K |
| Total liabilities | $1.8M | $318.3K | — | — | — | — | — | — | — | $218.7K |
| Retained earnings | -$58.1M | -$52.1M | -$48.5M | -$43.4M | -$37.1M | -$30.4M | -$27.1M | -$24.6M | -$22.5M | -$20.7M |
| Total equity | $9.7M | $827.2K | $4.0M | $5.2M | $4.8M | $5.0M | $2.4M | $4.1M | $995.0K | $214.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.1M | -$3.2M | -$4.3M | -$4.6M | -$4.1M | -$2.1M | $1.7M | -$1.5M | -$1.4M | -$1.7M |
| Stock-based compensation | $1.4M | $418.4K | — | $1.5M | $2.6M | $1.3M | $748.7K | $785.6K | — | — |
| Investing cash flow | -$3.2M | — | — | — | — | — | — | — | — | $104.1K |
| Financing cash flow | $10.3M | — | $3.1M | $5.1M | $3.9M | $4.6M | — | $4.5M | $2.5M | $1.7M |
| Buybacks | — | — | — | — | — | — | — | $24.7K | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014052.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |